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1. INTRODUCTION 
 
1.1 Major depression. 
 
Major depression is a severe psychiatric disorder that is the fourth leading cause of 
disability in the world, accounting for a relevant percentage of morbidity. It is a 
complex disorder characterized by the interaction of genetic, biological, social and 
environmental factors that play in concert to determine the development of the 
disease. Core symptoms include depressed mood, anhedonia (reduced ability to 
experience pleasure from natural rewards), irritability, difficulties in concentrating, 
abnormalities in appetite and sleep (‘neurovegetative symptoms’) and suicidal 
thoughts (Nestler, 2002). In addition to mortality associated with suicide, depressed 
patients are more likely to develop coronary artery disease and type 2 diabetes (Knol 
et al., 2006). The chronic, festering nature of depression contributes substantially to 
the global burden of disease and disability.  
Despite the prevalence of depression and its considerable impact, the knowledge 
about its pathophysiology is poor compared with other chronic and potentially fatal 
multifactorial conditions. Available techniques to document the aberrant function of 
brain circuits depend on either post-mortem studies, which have numerous 
limitations, or neuroimaging techniques, which rely on detecting changes in neuronal 
activity by using indirect markers of activation (Phelps and LeDoux, 2005). Despite 
these difficulties, several brain regions and circuits regulating emotion, reward, 
executive function and dysfunctional changes within these highly interconnected 
‘limbic’ regions have been implicated in depression and antidepressant action (Berton 
and Nestler, 2006). A large body of post-mortem (Sheline, 2003) and neuroimaging 
(Harrison, 2002) studies of depressed patients have reported reductions in grey-
matter volume and glial density in the prefrontal cortex and in the hippocampus, 
regions thought to mediate the cognitive aspects of depression, such as feelings of 
worthlessness and guilt. Although these approaches have provided important insights 
into candidate brain regions, simple increases or decreases in regional brain activity 
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are probably insufficient to explain the complex array of symptoms caused by 
depression. 
Therefore a clear pathogenetic mechanism is yet to be determined, but detailed 
studies have led to formulate different molecular theories of depression such as the 
“monoamine hypothesis” and the “neuroplasticity hypothesis”.  
The “monoamine hypothesis” of depression, which states that depression is caused 
by decreased monoamine function in the brain, originated from early clinical 
observations (Berton and Nestler, 2006; Pittenger and Duman, 2008). Two 
structurally unrelated compounds developed for non-psychiatric conditions, namely 
iproniazid and imipramine, had potent antidepressant effects in humans and were 
later shown to enhance central serotonin or noradrenaline transmission. Reserpine, 
an old antihypertensive agent that depletes monoamine stores, produced depressive 
symptoms in a subset of patients. Today’s antidepressant agents offer a better 
therapeutic index and lower rates of side effects for most patients, but they are still 
designed to increase monoamine transmission acutely (Berton and Nestler, 2006), 
either by inhibiting neuronal reuptake (for example, selective serotonin reuptake 
inhibitors (SSRIs) such as fluoxetine) or by inhibiting degradation (for example, 
monoamine oxidase inhibitors such as tranylcypromine). However, while monoamine 
oxidase inhibitors and SSRIs produce immediate increases in monoamine 
transmission, their mood-enhancing properties require weeks of treatment. 
Moreover a relevant percentage of patients does not show an adequate response to 
antidepressant therapy, or relapses into the pathology, possibly due to persistent 
symptomatology. Although these monoamine-based agents are potent 
antidepressants, and alterations in central monoamine function might contribute 
marginally to genetic vulnerability (Lopez-Leon et al., 2007; Ruhe et al., 2007), the 
cause of depression is far from being a simple deficiency of central monoamines. 
The “neuroplasticity hypothesis” of depression, suggests that mood disorders are 
caused by problems in information processing within particular neuronal circuits in 
the brain due to altered neuroplasticity, and that treatment with antidepressant 
drugs, may improve this deficit. Neuroplasticity is the ability of the brain to respond 
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and adapt to environmental challenges and encompasses a series of functional and 
structural mechanisms that may lead to neuronal remodeling, formation of novel 
synapses and birth of new neurons. Failure of such mechanisms might enhance the 
susceptibility to environmental challenges, such as stress, and ultimately lead to 
psychopathology. Neurotrophic factors play a key role as mediators of 
neuroplasticity. This aspect will be discussed in more detail later. 
In recent years it has become more evident that many factors can contribute to the 
development of this disease, such as the association between a vulnerable genetic 
background and different environmental factors, such as stress.  
Therefore, given the poor knowledge of the molecular mechanisms contributing to 
depression etiopathology and the unsuitability of the pharmacological treatment, 
several animal model of depression have been used, which could further our 
understanding of the pathophysiology of the disease, and also yield novel molecular 
mechanisms that may prove to be therapeutic targets for different antidepressants 
drugs. 
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1.2 Animal models of depression. 
 
An ideal animal model of depression would have identical causative factors, 
symptomatology and treatment modalities of the pathology. A number of symptoms 
of this disease, however, are clearly not measurable in preclinical paradigms, such as 
recurrent thoughts of death or suicide, or excessive thoughts of guilt. It is clear that 
evolutionary progression has provided humans with a much more elaborated 
cerebral cortex that facilitates integration of complex psychological concepts also 
relevant to human depression, such as self-esteem and the ability to perceive the 
future, which are absent in rodents (Cryan and Holmes, 2005). Despite these 
difficulties, a number of diverse animal models of depression have been widely used, 
many of them showing substantial construct validity (i.e., antidepressant 
administration reverses the behavioural parameters assessed). These animal models 
are often referred to as tests of antidepressant-like activity, given that they all have 
been validated since the introduction of clinically approved medications (Cryan and 
Slattery, 2007). This also renders the predictive validity of the models unclear until a 
novel acting compound from preclinical testing is successfully applied in humans.  
The most used animal models of depression are summarized in Table 1 (Calabrese et 
al., 2011). 
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Table 1. Traditional animal models used in depression research. 
 
Animal model Description 
Forced swim test (FST) 
Rodents are placed in an inescapable container of water. 
Swimming and climbing behaviours are evaluated and 
are increased with serotonergic or catecholaminergic 
antidepressants, respectively . 
Tail suspension test (TST) 
Rodents, chiefly mice, when hung from the tail will adopt 
an immobile posture. Antidepressant treatment 
increases the time animals spend in active behaviours. 
Learned helplessness  
Animals exposed to inescapable shocks subsequently fail 
to escape when able to. Antidepressant treatment 
increases the number of escapes, not all animals develop 
this helpless behavior. 
Olfactory bulbectomy  
Removal of the olfactory bulbs causes a constellation of 
behavioural and neurochemical alterations, which are 
only reversed by chronic antidepressant treatment 
Social stress  
Mice form stable subordinate relationship with a 
dominant, show behavioural and neurochemical 
alterations similar to depressed patients. A number of 
these alterations can be reversed with antidepressant 
treatment but the model requires further validation. 
Social isolation stress 
Animals were housed in their cages alone and are 
deprived of any social interaction. This model induce 
anxiety and depressive -like behaviors, that are reversed 
by antidepressant treatment. 
Chronic mild stress 
Animals are subjected to a variety of unpredictable 
stressors, which leads to a constellation of symptoms, 
that are reversed by antidepressant treatment. 
Prenatal stress 
Pregnant dams are usually exposed to different types of 
stressors from embryonic day 14 (E14) until delivery. 
Prenatally-stressed rats show a higher degree of 
immobility in the FST and reduced explorative behavior. 
Early life stress (ELS) 
When animals are separated from the mother during 
early postnatal life they can develop a number of 
depression-like behavioural characteristics. These 
behaviours are not present in all animals subjected to 
this treatment. 
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In the forced swim test (FST, also called the Porsolt test) animals are subjected to two 
trials during which they are forced to swim in an acrylic glass cylinder filled with 
water, and from which they cannot escape. The time that the animals spend without 
moving is associated to depressed behaviour. This immobility time is decreased by 
antidepressants. 
The tail suspension test (TST) is used to assay mood levels in rodents. Changes in 
immobility time indicate changes in mood. It is widely used to detect potential 
antidepressant effects of drugs. 
In the learned helplessness experiment an animal is repeatedly hurt by an adverse 
stimulus, which it cannot escape. Eventually the animal will stop trying to avoid the 
pain and behave as if it is utterly helpless to change the situation. Finally, when 
opportunities to escape are presented, this learned helplessness prevents any action. 
Chronic antidepressant treatment is able to revert this behavior in most of the cases 
(Nestler and Hyman, 2010). 
Chronic mild or chronic unpredictable stress involves subjecting normal rodents to a 
series of repeated stresses (food or water deprivation, crowding, isolation, soiled 
caged, restraint, foot shock or cold temperature) over a period of weeks or longer 
that leads to a chronic depressive-like state developed gradually over time (Willner, 
2005). At the end of the stress, the animals show signs of anhedonia (for example, 
reduced sucrose preference; face validity), which can be reversed by chronic, but not 
acute, administration of antidepressant medications (predictive validity).  
Chronic social defeat stress involves subjecting rodents to repeated bouts of social 
subordination, after which the rodents show a range of depression-like symptoms, 
including anhedonia and social withdrawal, which can be reversed by chronic, but not 
acute, antidepressants (Krishnan et al., 2007). Chronic social defeat also induces a 
metabolic syndrome in mice characterized by weight gain and insulin and leptin 
resistance (Chuang et al., 2010), consistent with homeostatic abnormalities observed 
in depression. A further advantage of chronic social defeat is that it can be used to 
study ‘resilience’, as a subset of mice, subjected to the same stress, fail to develop 
behavioral and metabolic disturbances. In contrast with all of these forms of ‘active’ 
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stress, it was recently found that prolonged exposure (weeks to months) of adult 
rodents to social isolation induces anhedonia that can be treated effectively with 
chronic antidepressants (Wallace et al., 2009).  
In the search for etiologically valid animal models of major depression, in recent 
years much hope has been placed in our ability to harness the power of genomics to 
resolve the genetic architecture of major depression heritability (estimated to 40%) 
and to identify causal mutations that can be reproduced in animals to emulate (in 
interaction with stress inducers discussed above) various aspect of behavioral and 
neural depression phenotypes. Several depression-like phenotypes have been 
reported in animals carrying mutations, which replicate naturally occurring single-
nucleotide polymorphisms that alter the function of candidate genes, such as the 
Brain Derived Neurotrophic Factor (BDNF). In particular BDNF Val66Met knock-in 
mice represent a strong model of predisposition to depression since these animals 
displayed hypothalamic-pituitary-adrenal axis hyperreactivity, increased depressive-
like and anxiety-like behaviors, (Soliman et al., 2010; Yu et al., 2012). In the context of 
mood disorder the serotonin transporter gene is also particularly relevant. The 
human serotonin transporter is encoded by a single gene, SLC6A4 (solute carrier 
family 6 member 4), whose transcriptional activity is modulated by genetic variants, 
including a functional polymorphism in the promoter region (5-HTTLPR), 
characterized by a long (L) and a short (S) variant. Specifically, functional studies 
confirmed that the L allele of the functional polymorphism 5-HTTLPR is associated 
with higher levels of transcriptional activity and higher rate of serotonin uptake with 
respect to the S variant (Murphy et al., 2008). Moreover, the L allele could be a 
protective factor for major depression, whereas the low-functioning allele is 
associated with increased disease susceptibility upon exposure to adverse life events 
(Caspi et al., 2003; Uher and McGuffin, 2008). Given that this polymorphism is 
present in humans and non-human primates, but not in rodents, rats and mice with a 
partial or total deletion of the SERT gene have been generated. Animal with a total 
deletion of the serotonin transporter displayed increased levels of anxiety- and 
depression-like behaviors (Holmes et al., 2003; Lira et al., 2003; Olivier et al., 2003). 
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For instance SERT-/- rats spent less time in the center part of the open field as well as 
on the open arm of the plus maze, suggesting an enhanced level of anxiety (Olivier et 
al., 2008).  
Several procedures have also disrupted an animal’s glucocorticoid homeostasis, 
based on derangements of the HPA axis in depression. To mimic the human situation 
of altered GR function claimed for depression, GR-heterozygous mutant mice (GR+/−) 
have been generated. These GR+/− mice have a predisposition for depression (Ridder, 
et al., 2005; Chourbaji and Gass, 2007; Molteni et al., 2010b), supporting the 
hypothesis that a dysfunction of corticosteroid receptors is involved in the 
pathogenesis of stress-related psychiatric disorders (Holsboer, 2000; DeRijk and de 
Kloet, 2008). Interestingly, behavioural abnormalities in these animals are not found 
at baseline, but manifest only after stress exposure, in agreement with the idea that 
gene * environment interaction is critical for the aetiology of mood disorders (Caspi, 
et al., 2003).  
Other animal models of depression are based on the evidence that stressful 
experiences during gestation or early in life can lead to enhanced susceptibility for 
mental illness. The negative influence exerted by adverse life events during gestation 
on brain development has received a great deal of attention since development 
represents a critical moment for shaping adult behavior and may set the stage to 
disease vulnerability later in life. In the majority of prenatal stress studies, pregnant 
dams have been exposed to stress as adverse manipulation and the short and long-
term behavioral and molecular changes in the newborns have been examined. Dams 
are usually exposed to different types of stressors (repeated daily immobilization 
under bright light, exposure to noise, sleep deprivation, immersion in cold-water) 
during the last week of gestation, from embryonic day 14 (E14) until delivery, 
although shorter periods of stress exposure have also been employed. Morley-
Fletcher and coworkers observed that prenatally-stressed rats show a higher degree 
of immobility in the forced swim test, if compared to rats with normal gestation 
(Morley-Fletcher et al., 2003). Similarly, prenatal stress reduces explorative behavior 
in adult rats, presumably due to decreased motivation (Patin et al., 2004; Secoli and 
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Teixeira, 1998; Vallee et al., 1997), a symptom often present in depressed patients. 
Moreover short- and long-term effects produced by prenatal stress may be the 
consequence of a direct interference with neurodevelopmental processes, but could 
also result from changes in post-partum maternal care (Champagne and Meaney, 
2006 ). 
The effects of early life stress (ELS) at adulthood have been investigated through a 
variety of experimental manipulations, the vast majority being based on the 
interference in mother-pup interaction, the so-called maternal deprivation (MD) 
paradigm. This procedure involves the removal of the pups from their mothers 
between birth and weaning for different periods of time, followed by testing the 
behavioral and molecular consequences when reaching adulthood. The best-studied 
paradigm consists of periods of daily separation (usually 3 hours) performed from 
postnatal day (PND) 2 to postnatal day 14, although a single 24 h period of removal at 
different postnatal ages has also been frequently employed. MacQueen and 
collaborators have shown that mice exposed to maternal separation for 3 h/day from 
PND 4 to PND 21 display, as adults, shorter swim time in the forced swim test, a 
behavioral despair that resembles depressive-like behavior (MacQueen et al., 2003). 
Moreover early postnatal stress led to changes in fear and emotional reactivity, 
which could also interfere with the cognitive test (Kosten et al., 2006; Romeo et al., 
2003). 
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1.3 Neuronal plasticity and BDNF. 
 
Neuronal plasticity refers to the ability of the nervous system to respond and adapt 
to environmental challenges and encompasses a series of functional and structural 
mechanisms that may lead to neuronal remodeling, formation of novel synapses and 
birth of new neurons. However, in a broader sense, neuronal plasticity is intimately 
linked to cellular responsiveness and may therefore be considered an index of the 
neuronal capability to adapt its function to a different demand. Failure of such 
mechanisms might enhance the susceptibility to environmental challenges, such as 
stress, and ultimately lead to psychopathology. That is to say that the brain, or more 
specifically, some brain structures or circuits, may become more vulnerable by 
loosing progressively (or suddenly) the ability to adapt and maintain their 
homeostasis. The manifestation of such vulnerability can be quite different according 
to the pathologic condition and may lead to overt degeneration (as occurring in 
neurodegenerative disorders) or to more subtle changes, leading to functional 
impairment, which represents a feature of psychiatric illness.  
Although the individual susceptibility threshold to environmental events may be 
genetically determined, it is believed that life events occurring during brain 
development may be critical for later psychopathology. Traumatic experiences 
occurring early in life may herein disrupt the correct program of maturation and 
eventually impact on brain function leading to a deterioration of neuronal plasticity. 
Indeed the brains of depressed subjects show structural abnormalities and reduced 
expression of several markers for neuronal function and viability, among which 
neurotrophic factors seem to be playing a pivotal role (aan het Rot et al., 2009; 
Sheline et al., 2003).  
Neurotrophic factors (NTFs), and in particular the neurotrophin family, are activity-
regulated genes that play an important role in network construction and 
reorganization, which are the main processes involved in neuroplasticity. In fact, 
besides their classical role in supporting neuronal survival, NTFs finely modulate all 
the crucial steps of network construction, from neuronal migration to experience-
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dependent refinement of local connections (Poo, 2001). These functions were first 
reported based on the observation that during the development of the nervous 
system, neuron survival depends on the limited amount of specific NTFs secreted by 
target cells (Huang and Reichardt, 2001). However, it is now well established that 
NTFs are important mediators of neuronal plasticity also in adulthood where they 
modulate axonal and dendritic growth and remodeling, membrane receptor 
trafficking, neurotransmitter release, synapse formation and function (Lu et al., 
2005). The neurotrophin BDNF has emerged as crucial mediator of neuronal 
plasticity, not only because it is abundant in brain regions that are particularly 
relevant for plasticity, but because it shows a remarkable activity-dependent 
regulation of its expression and secretion (Bramham and Messaoudi, 2005), 
suggesting that it might indeed bridge experience with enduring change in neuronal 
function. 
BDNF has a sophisticated organization in terms of transcriptional, translational and 
post translational regulatory mechanisms. With regard to BDNF transcription, its gene 
consists of nine 5’ untranslated exons, each linked to individual promoter regions, a 
3’ coding exon (IX), which codes for the BDNF pre-protein amino acid sequence, and 
two polyadenylation sites at the 3’ UTR (Aid et al., 2007). The transcription of each 
exons is driven by separate promoters in turn controlled by an array of signaling 
mechanisms, including Ca2+, CREB, CaRF, Npas4, USF, MeCP2, CaMKII and hormones 
(Zhou et al., 2006; Molteni et al., 2010a; Pruunsild et al., 2011). Furthermore it has 
been demonstrated that the transcription of specific BDNF splice variants is 
controlled by a variety of epigenetic mechanisms, including DNA methylation and 
post translational modifications of histones (Lubin et al., 2008; Molteni et al., 2010a; 
Roth et al., 2009). The regulation of specific promoters causes the temporal and 
spatial expression of specific BDNF transcripts (Lauterborn et al., 1996), some of 
which can undergo trafficking and targeting to dendrites (Chiaruttini et al., 2008), a 
process that may also be influenced by the 3’ untranslated region (UTR) of the 
neurotrophin (Ghosh et al., 1994; An et al., 2008).  
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Fig.1 Gene structure of BDNF and its transcripts.  
 
The BDNF protein is initially synthesized as proform that can either be cleaved into 
the mature neurotrophin or transported to the plasma membrane and released in an 
unprocessed manner. Several matrix metalloproteases (MMP) as well as plasmin are 
responsible for extracellular cleavage of the neurotrophin, whereas furin and specific 
proconvertases control its intracellular processing (Schweigreiter, 2006). Differently 
from other neurotrophins, BDNF can be secreted through a constitutive as well as a 
regulated pathway. The prodomain interacts with sortilin that promote an 
appropriate configuration of proBDNF. This, in turn, allows the sorting motif in the 
mature domain of BDNF to interact with carboxypeptidase E (CPE), and, therefore, to 
sort BDNF into the regulated secretory pathway. Thus, BDNF protein can be packaged 
into secretory vescicles (Lessmann et al., 2003) that are present in both axon 
terminals (presynaptic site) and dendrites (postsynaptic site) of glutamatergic 
neurons (Fawcett et al., 1997), from which the neurotrophin can be released in a 
Ca2+-dependent manner. Upon release, proBDNF and mBDNF have divergent 
activities, since the former binds with high affinity to p75NTR leading to apoptosis, 
whereas mBDNF binds to TrkB receptors promoting cell survival (Lu et al., 2005). 
Activated receptors in general are capable of triggering a number of signal 
transduction cascades including the mitogen-activated protein kinase (MAPK) 
pathway, the phosphatidylinositol 3-kinase (PI3K) pathway and the phospholipase C- 
(PLC-) pathway (Huang and Reichardt, 2001; Huang and Reichardt, 2003). 
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Fig.2 Intracellular signaling pathways activated by the binding of proBDNF with p75NTR and mBDNF with 
TrkB. 
 
An impairment of hippocampal BDNF signaling produces depression-related 
behaviors and impairs the actions of antidepressants (Monteggia et al., 2007; Taliaz 
et al., 2010). Hippocampal BDNF levels are reduced in postmortem samples from 
depressed humans (Karege et al., 2005). On the other hand experimental increases in 
hippocampal BDNF levels produce antidepressant-like effects (Hoshaw et al., 2005). 
BDNF’s role in depression has also been extensively studied in mutant mice. Lack of 
BDNF is not sufficient to produce a depressive phenotype (Chourbaji et al., 2004), but 
the neurotrophin is required for the behavioural response to antidepressant since the 
selective deletion of the BDNF gene in the hippocampal dentate gyrus, as well as the 
impaired function of its high affinity receptor TrkB, prevents behavioural responses to 
antidepressant drugs (Adachi et al., 2008; Monteggia et al., 2004;   et al., 2003).  
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2. AIM OF THE STUDY 
 
Major depression is a complex disorder characterized by the interaction of genetic, 
biological, social and environmental factors, which play in concert to determine the 
development of the disease. The serotonin transporter gene is of particular relevance 
in the context of mood disorders because it is the target of several antidepressant 
drugs and, due to the presence of a functional polymorphism within its promoter 
region, it has been associated with different neuropsychiatric disorders (Caspi et al., 
2003; Uher and McGuffin, 2008). Since the molecular mechanisms contributing to 
depression pathophysiology are still poorly understood, several genetic or 
environmental animal models of depression have been developed in order to 
reproduce the depressive phenotype and to characterize the molecular alterations of 
the disease. Among these, rodents (mice or rats) with a total deletion of the 
serotonin transporter represent a good model of anxiety and depression phenotypes  
and they have been extensively characterized at behavioral level (Holmes et al., 2003; 
Lira et al., 2003; Olivier et al., 2008), although a detailed analyses of the molecular 
phenotype associated with genetic alterations of SERT is still lacking. In particular, 
limited information exists on potential changes in neuronal plasticity, which is 
strongly associated with depression. Indeed it has been proposed that 
psychopathology may be associated with reduced expression and function of key 
mediators of neuronal plasticity, such as the neurotrophin brain-derived 
neurotrophic factor (BDNF), (McClung and Nestler, 2008; Pittenger and Duman, 
2008). 
Given all these premises, in this study, we investigated the expression of BDNF in 
different brain regions of adult SERT mutant rats (+/− and −/−). Moreover, since the 
neurotrophin has a complex genomic structure (Aid et al., 2007), we have 
investigated the influence of SERT deletion on its different transcripts and evaluated 
the involvement of several transcription factors in BDNF expression changes found in 
SERT mutant animals. 
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Moreover, considering that the depressive phenotype of SERT mutant animals 
appears to originate from the lack of the transporter during early life (Ansorge et al., 
2004; Ansorge et al., 2008), we also assessed when the neuroplastic alteration of 
SERT-/- animals are established, by investigating the expression of BDNF in SERT 
knockout rats during postnatal development. 
One system lying downstream from Npas4 and BDNF that may be relevant for the 
phenotype of SERT mutants is GABA. Indeed, Npas4 regulates the development of 
GABAergic synapses (Lin et al., 2008), while BDNF alteration can affect GABAergic 
cellular architecture and transmission (Sakata et al., 2009). Therefore we also 
established if SERT mutant rats are characterized by alterations in the expression of 
key GABAergic markers that may eventually contribute to the depressive phenotype 
of these animals. 
A further aspect of the experimental work is aimed at addressing the issue of gene * 
environment interaction in mood disorders. Indeed, stressful experiences can 
exacerbate or precipitate depressive disorder in genetically-prone individuals (Caspi 
et al., 2003). In particular adverse events early in life may impact on brain structures 
that are not completely matured resulting critical for the development of 
psychopathology later in life. In order to establish if the molecular phenotype 
associated with deletion of SERT gene could be modulated by early life events, we 
exposed SERT mutant rats (+/− and −/−) to maternal deprivation, a strong form of 
stress, and we assessed the expression of the neurotrophin BDNF as marker of 
neuronal plasticity. 
Last we investigated if pharmacological intervention in SERT mutant rats may restore 
neuroplastic defects associated with the vulnerable genotype. Therefore we 
chronically treated SERT knockout rats with the antidepressant duloxetine (a SNRI, 
dual blocker of the reuptake of the serotonin and norepinephrine) and we assessed 
its ability to normalize the expression of different neuroplastic genes that are 
significantly altered in mutant rats.  
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3. MATERIALS AND METHODS 
 
3.1 Serotonin transporter-knockout rats. 
 
SERT-knockout rats (Slc6a41Hubr) were generated by ENU-induced mutagenesis 
(Smits et al, 2006). All animals were bred and reared in the Central Animal Laboratory 
of the Radboud University Nijmegen Medical Centre in Nijmegen, The Netherlands. 
Experimental animals were derived from crossing heterozygous (SERT+/-) knockout 
rats for eight generations. After weaning at the age of 21 days, ear cuts were taken 
for genotyping. Animals were supplied with food and water ad libitum and were kept 
on a 12 h: 12 h dark–light cycle (lights on at 06:00 h). 
For basal analysis SERT+/-, SERT-/- rats, and their wild-type controls (SERT+/+), were 
sacrificed between 10 and 11 a.m. at adulthood (PND 90) whereas another cohort of 
SERT+/+ and SERT-/- rats was sacrificed at postnatal days (PND) 0, 7, 14, 21, 28, at the 
same timeslot. 
Brain regions of interest (ventral hippocampus, dorsal hippocampus and prefrontal 
cortex) were rapidly dissected. Dorsal hippocampus corresponds to plates 26-33 
(from Bregma -2.12 to Bregma -3.80), while ventral hippocampus corresponds to 
plates 34-43 (from Bregma -4.16 to Bregma -6.30) according to the atlas of Paxinos 
and Watson (1996). Prefrontal cortex (defined as Cg1, Cg3, and IL sub-regions 
corresponding to the plates 6-10 according to the atlas of Paxinos and Watson 
(1996)) was dissected from 2-mm thick slices. The brain specimens were frozen on 
dry ice and stored at -80°C for further analysis. All experiments were carried out in 
accordance with the guidelines laid down by the European Communities Council 
Directive of 24 November 1986 (86/609/EEC). 
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3.2 Maternal deprivation stress paradigm. 
 
The SERT+/+, SERT+/- and SERT-/- animals were bred and reared in the Central Animal 
Laboratory of the Radboud University Nijmegen Medical Centre in Nijmegen, The 
Netherlands. From postnatal day 2 to postnatal day 14 rats were separated from their 
mothers for 3 hours a day, while rats from the control group were briefly handled 
during bedding change. After this manipulation, all the animals underwent normal 
animal care and were sacrificed at adulthood (PND 90). Brain regions of interest 
(ventromedial prefrontal cortex and dorsomedial prefrontal cortex) were rapidly 
dissected. Ventromedial prefrontal cortex (IL cortex) and dorsomedial prefrontal 
cortex (PrL cortex) correspond to plates 9-11 (from Bregma -3.24 to Bregma -3.92) 
according to the atlas of Paxinos and Watson (1996)). The brain specimens were 
frozen on dry ice and stored at -80°C for further analysis. 
 
3.3 Pharmacological treatment of Serotonin transporter-knockout rats. 
 
Fluoxetine administration at adulthood in SERT+/+ and SERT-/- rats. 
To mimic the effect of SERT blockade at adulthood, separate cohorts of adult wild 
type and SERT−/− rats were randomly assigned to receive daily injections (between 
9:00 and 10:00 a.m.) of the selective-serotonin reuptake inhibitor fluoxetine (10 
mg/kg i.p.) or saline for 3 weeks. Twenty-four hours after the last injection the 
animals were sacrificed and the prefrontal cortex was dissected. Prefrontal cortex 
(defined as Cg1, Cg3, and IL sub-regions corresponding to the plates 6 to 10 according 
to the atlas of Paxinos and Watson (1996)) was dissected from 2-mm thick slices. The 
brain specimens were frozen on dry ice and stored at -80°C for further analysis.  
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Duloxetine treatment in SERT+/+ and SERT-/- rats. 
Adult SERT+/+ and SERT-/- rats were treated chronically (21 days) with saline (by 
gavage) or duloxetine (10 mg/kg, by gavage). Twenty-four hours after the last 
injection the animals were sacrificed and the brain regions of interest (whole 
hippocampus and prefrontal cortex) were rapidly dissected. Prefrontal cortex 
(defined as Cg1, Cg3, and IL sub-regions corresponding to the plates 6 to 10 according 
to the atlas of Paxinos and Watson (1996)) was dissected from 2-mm thick slices, 
whereas hippocampus was dissected from the whole brain. The brain specimens 
were frozen on dry ice and stored at -80°C for further analysis.  
 
3.4 RNA preparation and gene expression analysis by quantitative Real-time 
PCR. 
 
Total RNA was isolated by single step of guanidinium isothiocyanate/phenol 
extraction using PureZol RNA isolation reagent (Bio-Rad Laboratories s.r.l. Italia) 
according with the manufacturer’s instructions and quantified by spectrophotometric 
analysis. Following total RNA extraction, the samples were processed for real-time 
polymerase chain reaction (PCR) to assess total Brain derived neurotrophic factor 
(BDNF), long 3’ UTR BDNF, BDNF exons I, IV, VI, neuronal PAS domain protein 4 
(Npas4), cAMP responsive element-binding protein (CREB), calcium-responsive 
transcription factor (CaRF), 2 subunit of GABAA receptor (GABAA 2), Glutamic acid 
decarboxylase 1 (Gad67), Vescicular-GABA Transporter (Vgat), Parvalbumin (Pvalb) 
and Calbindin (Calb1) mRNA levels. An aliquot of each sample was treated with 
DNase to avoid DNA contamination. RNA was analyzed by TaqMan qRT-PCR 
instrument (CFX384 real time system, Bio-Rad Laboratories, Italy) using the iScriptTM 
one-step RT-PCR kit for probes (Bio-Rad Laboratories). Samples were run in 384 well 
formats in triplicate as multiplexed reactions with a normalizing internal control 
(36B4 or 18S). Probe and primer sequences used (Table 1) were purchased from 
Eurofins MWG-Operon (Germany) and Life Technologies. 
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Thermal cycling was initiated with an incubation at 50°C for 10 min (RNA 
retrotranscription) and then at 95°C for 5 min (TaqMan polymerase activation). After 
this initial step, 39 cycles of PCR were performed. Each PCR cycle consisted of heating 
the samples at 95°C for 10 s to enable the melting process and then for 30 s at 60°C 
for the annealing and extension reactions. A comparative cycle threshold (Ct) method 
was used to calculate the relative target gene expression. 
 
3.5 Preparation of protein extract and Western blot analysis. 
 
Western blot analysis was used to investigate BDNF protein levels in the total 
homogenate and in the crude synaptosomal fraction. Tissues were manually 
homogenized using a glass-glass potter in a pH 7.4 cold buffer containing 0.32 M 
sucrose, 0.1 mM EGTA, 1mM HEPES solution in presence of a complete set of protease 
(Roche) and phosphatase (Sigma-Aldrich) inhibitors. The total homogenate was 
centrifuged at 2,500 rpm for 10 min at 4°C. The supernatant obtained was centrifuged 
at 10,000 g for 15 min at 4°C to obtain a pellet (P2) corresponding to the crude 
synaptosomal fraction which was re-suspended in a buffer (20mM HEPES, 0.1 mM 
dithiothreitol (DTT), 0.1 mM EGTA) with protease and phosphatase inhibitors. Total 
protein content was measured according to the Bradford Protein Assay procedure 
(Bio-Rad Laboratories), using bovine serum albumin as calibration standard.  
Equal amounts of protein were run under reducing conditions on the criterion TGX 
precast gels (Bio-Rad Laboratories) and then electrophoretically transferred onto 
PVDF membranes (Bio-Rad Laboratories). The blots were blocked with 10% nonfat 
dry milk and then incubated with the anti-BDNF rabbit polyclonal antibody (1:500, 
4°C, overnight; Santa Cruz Biotechnology) able to recognize both the mature form of 
the neurotrophin (mBDNF; 14 kDa) and its precursor (proBDNF; 32 kDa). Membranes 
were then incubated for 1 h at room temperature with a peroxidase-conjugated anti-
rabbit IgG (1:1.000) and immunocomplexes were visualized by chemiluminescence 
using the Chemidoc MP Imaging System (Bio-Rad Laboratories). Results were 
standardized using -actin as the control protein, which was detected by evaluating 
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the band density at 43 kDa after probing the membranes with a mouse polyclonal 
antibody (1:10.000, Sigma–Aldrich) followed by a 1:10.000 dilution of peroxidase-
conjugated anti-mouse IgG (Sigma–Aldrich). Protein levels were calculated by 
measuring the optical density of the autoradiographic bands using Quantity One 
software (Bio-Rad Laboratories). To ensure that autoradiographic bands were in the 
linear range of intensity, different exposure times were used. 
 
3.6 Statistical analyses. 
 
All the analyses were carried out in individual animals (independent determinations). 
The effect of genotype and/or antidepressant treatment on mRNA levels was 
analyzed with a two-way analysis of variance (ANOVA) followed by Single Contrast 
Post Hoc Test (SCPHT), one-way analysis of variance (ANOVA) followed by Bonferroni 
Post Hoc Test or Student t-test. Pearson product moment correlations (r) between 
levels of Npas4 mRNAs and GABAA-2 mRNAs were performed to evaluate the 
correlation between the expression levels of the two genes in single animals. 
Significance for all tests was assumed for p<0.05 Data are presented as means  
standard error (S.E.M.). 
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Table 2. Sequences of forward and reverse primers and probes used in Real-Time 
PCR analysis.  
 
a: forward and reverse primers and probes purchased from Eurofins MWG-Operon 
Gene Forward primer Reverse Primer Probe 
Total Bdnf 5’-AAGTCTGCATTACATTCCTCGA-3’ 5’-GTTTTCTGAAAGAGGGACAGTTTAT-3’ 5’-TGTGGTTTGTTGCCGTTGCCAAG-3’ 
Npas4 5’-GGAAGTTGCTATACCTGTCGG-3’ 5’-GTCGTAAATACTGTCACCCTGG-3’ 5’-CATAGAATGGCCCAGATGCTCGCT-3’ 
Creb 5’-AGATTCTAGTGCCCAGCAAC-3’ 5’-CTGTGCGAATCTGGTATGTTTG-3’ 5’-TGTTCAAGCTGCCTCTGGTGATGT-3’ 
Carf 5’-GAGATGCACACACCATTCCA-3’ 5’-GTGTTGGCTCATTGGGTTCT-3’ 5’-CAGCCATCCAGCTCTTGTTGAAGA-3’ 
GABAA2 5’-ACTCATTGTGGTTCTGTCCTG-3’ 5’-GCTGTGACATAGGAGACCTTG-3’ 5’-ATGGTGCTGAGAGTGGTCATCGTC-3’ 
Gad67 5’-ATACTTGGTGTGGCGTAGC-3’ 5’-AGGAAAGCAGGTTCTTGGAG-3’ 5’-AAAACTGGGCCTGAAGATCTGTGGT-3’ 
Vgat 5’-ACGACAAACCCAAGATCACG-3’ 5’-GTAGACCCAGCACGAACATG-3’ 5’-TTCCAGCCCGCTTCCCACG-3’ 
Pvalb 5’-CTGGACAAAGACAAAAGTGGC-3’ 5’-GACAAGTCTCTGGCATCTGAG-3’ 5’-CCTTCAGAATGGACCCCAGCTCA-3’ 
Calb1 5’-AGAACTTGATCCAGGAGCTTC-3’ 5’-CTTCGGTGGGTAAGACATGG-3’ 5’-TGGGCAGAGAGATGATGGGAAAATAGGA-3’ 
18S 5’-GTAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’ 5’-TGCAATTATTCCCCATGAACGAGG-3’ 
36B4 5’-TTCCCACTGGCTGAAAAGGT-3’ 5’-CGCAGCCGCAAATGC-3’ 5’-AAGGCCTTCCTGGCCGATCCATC-3’ 
b:   forward and reverse primers and probes purchased from Life Technologies 
Gene Accession number Assay ID 
Long 3’UTR Bdnf EF125675 Rn02531967_s1 
Bdnf exon I EF125675 Rn01484924_m1 
Bdnf exon IV EF125678 Rn01484927_m1 
Bdnf exon VI EF125680 Rn01484928_m1 
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4. RESULTS 
 
4.1 Lack of serotonin transporter is associated with reduced basal Brain 
Derived Neurotrophic Factor (BDNF) expression in different brain regions. 
 
Animals with SERT gene deletion represent an important tool to identify the 
molecular mechanisms contributing to the association between mood disorders and 
the life-long dysfunction of the serotonin transporter. Indeed SERT knockout rodents 
show depression- and anxiety-related behaviour (Olivier et al., 2008, Kalueff et al., 
2009) supporting the possibility that altered function of SERT may indeed be 
associated with increased risk for mood disorders (Gardier, 2009). 
We initially investigated possible changes in the expression of the neurotrophin 
BDNF, a key marker of neuroplasticity. Indeed, during the last few years it has 
become apparent that several psychiatric conditions, such as mood disorders, are 
associated with deficits or impairment of neuronal plasticity (Krishnan and Nestler, 
2008; Pittenger and Duman, 2008, Calabrese et al., 2009). Our analyses were 
performed in the ventral and the dorsal hippocampus, two different hippocampal sub 
regions with different anatomical connectivity and functional implications (Fanselow 
and Dong 2010), and in the prefrontal cortex of SERT+/- and SERT-/- animals. Total 
BDNF mRNA levels are significantly reduced in the ventral hippocampus of SERT-/- rats 
(−50% vs SERT+/+, p<0.05) (Fig.3A) but not in the dorsal hippocampus (−9% vs SERT+/+, 
p>0.05) (Fig.3B). The neurotrophin is also significantly reduced in the prefrontal 
cortex of adult SERT+/- (-16% vs SERT+/+, p<0.001) and SERT-/- rats (-34% vs SERT+/+, 
p<0.001) (Fig.3C).  
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Fig.3 Deletion of SERT gene modulates BDNF gene expression in ventral hippocampus, dorsal hippocampus 
and in the prefrontal cortex. 
Total BDNF mRNA levels were measured in the ventral hippocampus (A), in the dorsal hippocampus (B) and in 
the prefrontal cortex (C) of SERT
+/-
 and SERT
-/-
 rats, as compared to their wild-type (SERT
+/+
) counterparts. The 
data, expressed as a percentage of +/+ animals (set at 100%), are the mean±SEM from 6 to 14 independent 
determinations. *p<0.05, ***p<0.001 vs SERT+/+ rats (one-way ANOVA with Bonferroni post hoc test). 
 
It is known that the BDNF gene has a complex organization, and it is transcribed from 
at least eight promoters, which drives the transcription of a 5’ exon alternatively 
spliced onto a common 3’ exon-encoding BDNF protein (Aid et al., 2007). On this 
basis, we investigated the expression levels of the long 3’ UTR BDNF and of the exons 
I, IV and VI since, up to date, their promoters have been well characterized (Takeuchi 
et al., 2002, Pruunsild et al., 2011). 
In the ventral hippocampus the mRNA levels of exon I and exon IV are significantly 
reduced in SERT-/- rats (respectively -37% vs SERT+/+, p<0.05; -35% vs SERT+/+, p<0.01) 
(Fig.4B,C), while long 3’ UTR BDNF and exon VI are not modulated in mutant rats 
(respectively +2% vs SERT+/+, p>0.05; -14% vs SERT+/+, p>0.05) (Fig.4A,D). Moreover 
exon I expression is also reduced in SERT heterozygous rats (-34% vs SERT+/+, p<0.05).  
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Fig.4 Deletion of SERT gene modulates long 3’UTR BDNF, exon I, exon IV and exon VI gene expression in the 
ventral hippocampus. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the ventral 
hippocampus of SERT+/- and SERT-/- rats, as compared to their wild-type (SERT+/+) counterparts. The data, 
expressed as a percentage of +/+ animals (set at 100%), are the mean±SEM from 6 to 8 independent 
determinations. *p<0.05, **p<0.01 vs SERT+/+ rats (one-way ANOVA with Bonferroni post hoc test). 
 
In the dorsal hippocampus we found a significant reduction of BDNF exon VI in SERT+/- 
rats (-40% vs SERT+/+, p<0.05), but not in SERT-/- (-33% vs SERT+/+, p>0.05) (Fig.5D). On 
the other hand the other three transcripts are not influenced by the lack of the 
serotonin transporter in heterozygous (long 3’ UTR BDNF: +15% vs SERT+/+, p>0.05; 
exon I: -3% vs SERT+/+, p>0.05; exon IV: +38% vs SERT+/+, p>0.05) as well as in knock 
out rats (long 3’ UTR BDNF: -6% vs SERT+/+, p>0.05; exon I: -17% vs SERT+/+, p>0.05; 
exon IV: +28% vs SERT+/+, p>0.05) (Fig.5A-C).  
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Fig.5 Deletion of SERT gene modulates long 3’UTR BDNF, exon I, exon IV and exon VI gene expression in the 
dorsal hippocampus. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the dorsal 
hippocampus of SERT+/- and SERT-/- rats, as compared to their wild-type (SERT+/+) counterparts. The data, 
expressed as a percentage of +/+ animals (set at 100%), are the mean±SEM from 6 to 8 independent 
determinations. *p<0.05 vs SERT+/+ rats (one-way ANOVA with Bonferroni post hoc test). 
 
Finally in the prefrontal cortex we found a reduction of BDNF exon I and IV mRNA 
levels in both heterozygous (exon I: -15% vs SERT+/+, p<0.01; exon IV: -18% vs SERT+/+, 
p<0.05) and SERT knock out rats (exon I: -19% vs SERT+/+, p<0.001; exon IV: -33% vs 
SERT+/+, p<0.001) (Fig.6B,C). On the other hand long 3’ UTR BDNF transcript and exon 
VI are reduced only in SERT-/- rats (respectively -25% vs SERT+/+, p<0.05; −30% vs 
SERT+/+, p<0.001).  (Fig.6A,D). 
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Fig.6 Deletion of SERT gene modulates long 3’UTR BDNF, exon I, exon IV and exon VI gene expression in the 
prefrontal cortex. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the prefrontal 
cortex of SERT+/- and SERT-/- rats, as compared to their wild-type (SERT+/+) counterparts. The data, expressed as 
a percentage of +/+ animals (set at 100%), are the mean±SEM from 7 to 14 independent determinations. 
*p<0.05, **p<0.01, ***p<0.001 vs SERT+/+ rats (one-way ANOVA with Bonferroni post hoc test). 
 
In order to evaluate if the modulation of BDNF gene expression observed in the 
ventral hippocampus, dorsal hippocampus and in the prefrontal cortex of SERT 
mutant rats was paralleled by similar effects at translational level, we performed 
western blot analysis of the crude synaptosomal fraction from these animals. We 
found that in the ventral hippocampus (Fig.7A,B) the precursor form of the 
neurotrophin (proBDNF) is not modulated in SERT-/- rats, while the mature BDNF is 
significantly reduced in mutant rats (-34% vs SERT+/+, p<0.05). Conversely in the 
dorsal hippocampus (Fig.7C,D), proBDNF is reduced in SERT-/- animals (-33%, vs 
SERT+/+, p<0.05) and mBDNF protein levels are slightly but not significantly affected 
by lack of the serotonin transporter (-36% vs SERT+/+, p>0.05). 
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Similarly to the dorsal hippocampus, the levels for mature BDNF were unchanged at 
cortical level (Fig.7E,F) (-6% vs SERT+/+, p>0.05), while the levels of the precursor form 
were significantly reduced in SERT-/- rats (−31% vs SERT+/+, p<0.01). 
 
Fig.7 Altered levels of BDNF protein in the ventral hippocampus, in the dorsal hippocampus and in the 
prefrontal cortex of SERT mutant rats. 
The precursor of the neurotrophin (proBDNF) (A,C,E) and its mature form (mBDNF) (B,D,F) were measured in 
the crude synaptosomal fraction of ventral hippocampus (A,B), dorsal hippocampus (C,D) and in the prefrontal 
cortex (E,F) of SERT-/- rats, as compared to their wild-type (SERT+/+) counterparts. The data, expressed as a 
percentage of +/+ animals (set at 100%), are the mean±SEM from 6 to 14 independent determinations.  
*p<0.05 vs SERT+/+ rats (Student t-test). 
 
The reduction of BDNF expression observed in SERT mutant rats might be due to the 
lack of the transporter during the entire life, encompassing development as well as 
adulthood. To discriminate between these possibilities, we have used a 
pharmacological strategy and we investigated the neurotrophin expression in the 
prefrontal cortex after subchronic (21 days) treatment of adult wild type and mutant 
rats with fluoxetine, a selective-serotonin reuptake inhibitor. Indeed, as shown in 
Fig.8, the antidepressant significantly increased total BDNF mRNA levels in wild type 
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rats (+32% vs SERT+/+/veh, p<0.01). Conversely, the reduced neurotrophin expression 
in vehicle-injected SERT-/- rats (−40% vs SERT+/+/veh, p<0.001) was not significantly 
affected by fluoxetine administration (-50% vs SERT+/+/flx, p<0.001). These results 
suggest that prolonged blockade of SERT at adulthood is not sufficient to determine 
the reduction of BDNF expression observed in SERT-/- rats. Moreover, the lack of 
fluoxetine effect in SERT mutant rats confirms that these animals do not express a 
functional serotonin transporter. 
Since impairment of SERT in adulthood does not appear to be responsible for BDNF 
down-regulation in the prefrontal cortex, it is feasible to hypothesize that the 
reduction of the neurotrophin may represent a long-lasting consequence of 
transporter dysfunction during development, in agreement with what has been 
shown for the behavioural phenotype of SERT-/- mice (Ansorge et al., 2004). 
 
Fig.8 Chronic fluoxetine treatment increases total BDNF mRNA levels in prefrontal cortex of adult wild-type 
rats but not in SERT-/- rats.  
SERT+/+ and SERT−/− rats received daily injection of the selective-serotonin reuptake inhibitor fluoxetine (10 
mg/kg i.p.) or vehicle for 3 weeks (n=8 each experimental group). Twenty-four hours after the last injection, the 
animal were sacrificed, the prefrontal cortex was dissected and used to measure total BDNF gene expression. 
The data, expressed as a percentage of SERT+/+/veh (set at 100%), are the mean±SEM from at least 6 
independent determinations.  
**p<0.01, ***p<0.001 vs. SERT+/+/veh; $$$ p<0.001 vs. SERT+/+/FLX (two-way ANOVA with SCPHT). 
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4.2 Developmental influence of the serotonin transporter on the expression 
of the neurotrophin BDNF. 
 
The serotonin transporter is expressed much more broadly during development than 
in adulthood and it is conceivable that perturbation of SERT expression and function 
during critical periods early in development might lead to detrimental consequences 
later in life. Moreover SERT is arguably the predominant mechanism controlling the 
strength and duration of serotonergic neurotransmission, which plays a particularly 
salient role as a developmental signal, important for the proper wiring of neural 
circuits (Levitt et al., 1983; Gaspar et al., 2003). Therefore, in order to identify when 
the neuroplastic alteration of SERT-/- animals are established, we investigated the 
gene expression of BDNF in different brain region of SERT knockout rats at different 
ages of life. Given the complex genomic structure of the neurotrophin (Pruunsild et 
al., 2011), we also investigated the influence of the lack of SERT during development 
on different BDNF transcripts. 
First, we investigated the levels of total BDNF mRNA levels in the ventral and the 
dorsal hippocampus and in prefrontal cortex, and we observed an overall reduction 
of the neurotrophin gene expression in SERT mutant rats.  
Specifically, in the ventral hippocampus (Fig.9A), even if a decrease of BDNF 
expression is detected in the SERT-/- rats compared to SERT+/+ already at birth (PND0: 
-23% vs SERT+/+, p>0.05), the effect became statistically significant starting from PND 
14 (-25% vs SERT+/+, p<0.05) and became more considerable at PND 21 (-41% vs 
SERT+/+, p<0.001) and PND 28 (-50% vs SERT+/+, p<0.001). This is probably due to the 
fact that in the mutant rats BDNF mRNA levels remain relatively constant from the 
second week of life, whereas there is a progressive increase in SERT+/+ rats.  
In the dorsal hippocampus (Fig.9B) the BDNF transcript levels are strongly reduced in 
SERT-/- animals at birth (PND0: -43% vs SERT+/+, p<0.01) and remain reduced in 
mutant rats during the first four weeks of life (PND7: -39% vs SERT+/+, p<0.05; PND14: 
-32% vs SERT+/+, p<0.05; PND21: -32% vs SERT+/+, p<0.05; PND28: -32% vs SERT+/+, 
p<0.05).  
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As shown in Fig.9C, in the prefrontal cortex BDNF mRNA levels increased 7-fold in 
wild-type animals between PND7 and PND14 while, interestingly, in the mutant rats 
the reduction of the neurotrophin gene expression due to the lack of the SERT is 
established in the same time window since it begins at PND7 (-38% vs SERT+/+, 
p<0.01) and remained stable in the subsequent post natal days (PND14: -46% vs 
SERT+/+, p<0.001; PND21: -40% vs SERT+/+, p<0.001; PND28: -27% vs SERT+/+, p<0.001). 
 
 
 
Fig.9 Developmental analysis of BDNF expression changes in SERT-/- rats. 
BDNF mRNA levels were measured in the ventral hippocampus (A), in the dorsal hippocampus (B) and in the 
prefrontal cortex (C) of SERT-/- and SERT+/+ rats at postnatal days (PND) 0, 7, 14, 21, 28. The data, expressed as 
fold change (where Ct is the difference between the threshold cycle of the target gene and the housekeeping 
gene) and as a percentage of wild-type animals at each PND (set at 100%), are the mean ± SEM of 6-12 
independent determinations. *p<0.05, **p<0.01, ***p<0.001 vs SERT+/+ rats (Student t-test). 
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We next investigated the expression levels of the long 3’ UTR BDNF and of the exons 
I, IV and VI in the three areas. 
In the ventral hippocampus, the mRNA levels of long 3’UTR BDNF and exon VI (Fig. 
10A,D) show a similar pattern of expression that also parallels the changes observed 
for the total form of the neurotrophin. Moreover, the trend is the same between 
SERT+/+ and SERT-/-, but both the transcripts mRNA levels are decreased already from 
birth in the mutant rats. 
Conversely, no difference in the expression levels of exons I and IV (Fig.10B,C) are 
observed between SERT-/- and SERT+/+ at PND0. In wild type rats the expression of 
both the transcripts strongly increased from birth until PND14 and remained constant 
thereafter. On the contrary, in SERT-/- animals, starting from PND7 we observed a 
significant decrease of exon I expression, effect that remained similar at PND14, and 
became slightly more pronounced in the following time points analysed. Differently, 
BDNF exon IV mRNA levels are fully comparable between SERT+/+ and SERT-/- until 
PND 14, whereas starting from PND21 we found a statistically significant reduction. 
Notably, the mRNA levels of exon IV in the wild type increased up PND 14 and then 
remain stable whereas, after this age, in the mutant rats we observed a decline of 
exon IV expression. 
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Fig.10 Developmental analysis of BDNF isoforms expression changes in the ventral hippocampus of SERT -/- 
rats. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the ventral 
hippocampus of SERT+/+ and SERT-/- rats at postnatal days (PND) 0, 7, 14, 21, 28. The data, expressed as fold 
change (where Ct is the difference between the threshold cycle of the target gene and the housekeeping 
gene), are the mean ± SEM of 6-12 independent determinations. *p<0.05, **p<0.01, ***p<0.001 vs SERT+/+ rats 
(Student t-test). 
 
In the dorsal hippocampus we found a similar modulation of long 3’UTR BDNF and 
exon VI in SERT-/- rats. Specifically long 3’UTR BDNF transcript is significantly reduced 
starting from PND14, while exon VI from PND21 and their reduction remains stable 
until PND28 (Fig.11A,D). Exon IV expression is decreased in SERT-/- animals since 
PND0 and the reduction remains stable in the subsequent post natal days (Fig.11C). 
Conversely we did not found any reduction of exon I mRNA levels between SERT-/- 
and SERT+/+, with the exception of PND7 in which the neurotrophin levels are slightly 
but significantly reduced in mutant rats (Fig.11B). 
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Fig.11 Developmental analysis of BDNF isoforms expression changes in the dorsal hippocampus of SERT-/- 
rats. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the dorsal 
hippocampus of SERT+/+ and SERT-/- rats at postnatal days (PND) 0, 7, 14, 21, 28. The data, expressed as fold 
change (where Ct is the difference between the threshold cycle of the target gene and the housekeeping 
gene), are the mean ± SEM of 6-12 independent determinations.  
*p<0.05, **p<0.01 vs SERT+/+ rats (Student t-test). 
 
In the prefrontal cortex (Fig.12A-D) we found a homogenous pattern of modulation 
for all the transcripts measured through the different periods of life that also parallels 
total BDNF mRNA expression. Indeed, no changes are observed at PND0, whereas 
from postnatal day 7 all the isoforms analysed appear to be reduced in SERT-/- 
compared to SERT+/+. Interestingly, in SERT+/+ rats the expression of all the exons 
examined underwent a sharp increase from PND7 to PND14, an effect that was 
smaller in SERT-/- rats, thus determining the difference that remains relatively stable 
thereafter.  
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Fig.12 Developmental analysis of BDNF isoforms expression changes in the prefrontal cortex of SERT-/- rats. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the prefrontal 
cortex of SERT+/+ and SERT-/- rats at postnatal days (PND) 0, 7, 14, 21, 28. The data, expressed as fold change 
(where Ct is the difference between the threshold cycle of the target gene and the housekeeping gene), are 
the mean ± SEM of 6-12 independent determinations.  
*p<0.05, **p<0.01, ***p<0.001 vs SERT+/+ rats (Student t-test). 
 
In order to investigate if the reduction of BDNF mRNA levels was associated to similar 
changes at translational levels, we measured the levels of proBDNF and mBDNF in the 
crude synaptosomal fraction, which may represent a ready-to-use pool of the 
neurotrophin (Poo, 2001). We decided to perform the analysis in the ventral 
hippocampus and in the prefrontal cortex at postnatal days 7 and 21, since at PND7 
we found a partial decrease of the neurotrophin, while at PND21 the reduction of 
BDNF is fully established.  
In the ventral hippocampus (Fig.13A,B) of PND 7 rats there were no significant 
differences in the levels of both proBDNF as well as mBDNF (+5% vs SERT+/+, p>0.05, -
12% vs SERT+/+, p>0.05, respectively) between genotypes, whereas at PND21 the 
levels of mBDNF were significantly reduced in SERT-/- rats as compared to SERT+/+ rats 
(-50% vs SERT+/+, p<0.01) (Fig.13D). A reduction was found also for proBDNF even if 
this effect did not reach statistical significance (-33% vs SERT+/+,  p>0.05) (Fig.13C). 
Similarly, in the prefrontal cortex of PND7 rats (Fig.13E,F) the deletion of the SERT 
gene did affect the levels of neither proBDNF (-28% vs SERT+/+, p>0.05) nor mBDNF 
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(+12% vs SERT+/+, p>0.05) in the crude synaptosomal fraction. Conversely, at PND21 
(Fig.13G,H), the levels of mBDNF were significantly reduced in SERT-/- rats compared 
to SERT+/+ rats (-49% vs SERT+/+, p<0.05). The alteration of proBDNF, however, did not 
reach statistical significance (-41% vs SERT+/+, p>0.05). 
 
 
Fig.13 Analysis of BDNF protein levels in the SERT-/- rats during development. 
The protein levels of the precursor (A, C, E, G) and the mature (B, D, F, H) forms of BDNF were measured in the 
ventral hippocampus (A, B, C, D) and in the prefrontal cortex (E, F, G, H) of SERT+/+ and SERT-/- rats at postnatal 
days (PND) 7 (A, B, E, F) and 21 (C, D, G, H). The data, expressed as a percentage of wild type (set at 100%), are 
the mean ± SEM of 5-10 independent determinations.  
*p<0.05, **p<0.01 vs. SERT+/+ rats (Student t-test). 
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4.3 Disruption of SERT affects the expression levels of transcription factors 
regulating BDNF. 
 
As mentioned before, the BDNF gene has a very complex structure that gives rise to 
multiple transcripts (Aid et al, 2007; Greer and Greenberg, 2008; Pruunsild et al., 
2011). Among the various mechanisms that might potentially underlie the difference 
of the BDNF expression between SERT+/+ and SERT-/- rats, we investigated the 
expression of the transcription factors Npas4, CREB and CaRF, which cooperate and 
interact to regulate the transcription of the exon IV (Pruunsild et al., 2011) which is 
the most abundant and well-characterized BDNF transcript.  
 
 
Fig.14 Alignment of the region responsible for neuronal activity-dependent induction of BDNF exon IV in 
human and rat. PasRE, CaRE and CRE designate the response elements for the respective transcription 
factors Npas4, CREB and CaRF. 
 
In line with the modulation of BDNF transcript IV, in the ventral hippocampus, we 
found a significant reduction of Npas4 (-28% vs SERT+/+, p<0.01), CREB (-36% vs 
SERT+/+, p<0.01) and CaRF (-44% vs SERT+/+, p<0.01) in adult SERT-/- rats compared to 
wild type animals (Fig.15). 
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Fig.15 Deletion of SERT gene modulates transcription factors gene expression in ventral hippocampus of 
SERT-/- rats. 
The mRNA levels of neuronal PAS domain protein 4 (Npas4) (A), cAMP response element-binding (CREB) (B) 
and Calcium-Response Factor (CaRF) (C) were measured in the ventral hippocampus of SERT-/- rats, as 
compared to their wild-type (+/+) counterparts. The data, expressed as a percentage of +/+ animals (set at 
100%), are the mean±SEM from 6 to 10 independent determinations.  
**p<0.01 vs SERT+/+ rats (Student t-test). 
 
In the dorsal hippocampus (Fig.16) we found that only Npas4 is significantly reduced 
in SERT-/- animals (-27% vs SERT+/+, p<0,01), while the mRNA levels of CREB and CaRF 
are not modulated by the lack of SERT (respectively -18% vs SERT+/+, p>0.05; -26% vs 
SERT+/+, p>0.05).  
 
 
Fig.16 Deletion of SERT gene modulates transcription factors gene expression in dorsal hippocampus of SERT-
/- rats.  
The mRNA levels of neuronal PAS domain protein 4 (Npas4) (A), cAMP response element-binding (CREB) (B) 
and Calcium-Response Factor (CaRF) (C) were measured in the dorsal hippocampus of SERT-/- rats, as compared 
to their wild-type (+/+) counterparts. The data, expressed as a percentage of +/+ animals (set at 100%), are the 
mean±SEM from 6 to 10 independent determinations.  
**p<0.01 vs SERT+/+ rats (Student t-test). 
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Finally, as shown in Fig.17, both Npas4 (-45%, p<0.001 vs SERT+/+) and CaRF (-27%, 
p<0.05, vs SERT+/+) expression is reduced in the prefrontal cortex of SERT-/- animals, 
suggesting that alterations in the expression and function of these transcription 
factors may sustain the reduction of exon IV mRNA levels observed at adulthood. 
Conversely SERT disruption does not affect CREB mRNA levels (+7% vs SERT+/+, 
p>0.05,).  
 
 
Fig.17 Deletion of SERT gene modulates transcription factors gene expression in the prefrontal cortex of 
SERT-/- rats.  
The mRNA levels of neuronal PAS domain protein 4 (Npas4) (A), cAMP response element-binding (CREB) (B) 
and Calcium-Response Factor (CaRF) (C) were measured in the prefrontal cortex of SERT-/- rats, as compared to 
their wild-type (+/+) counterparts. The data, expressed as a percentage of +/+ animals (set at 100%), are the 
mean±SEM from 6 to 10 independent determinations.  
*p<0.05, ***p<0.001 vs SERT+/+ rats (Student t-test). 
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4.4 Animals with a deletion of SERT gene show impaired expression of 
GABAergic markers. 
 
Recently, Npas4 has been shown to control GABAergic synapse development through 
a program of activity-dependent gene development. In particular, Npas4-RNA 
interference reduced the density of GABAA receptor, gamma 2 (GABAA 2) and GABA-
2/3 receptors, and of GABA-producing enzymes glutamic acid decarboxylase 
(Gad)65 and Gad67 (Lin et al, 2008). Moreover clinical and preclinical studies support 
a central and causal role of the GABAergic system in the etiology of depressive 
disorders (Luscher et al, 2011; Sanacora et al, 1999). This led us to hypothesize that 
the transcription factor Npas4, which is altered in SERT-/- rats, may eventually link 
alterations of BDNF, with an impaired function of the GABAergic system. 
Therefore we investigated the expression of three key elements of the GABAergic 
synapses: the GABA vesicular transporter Vgat, the GABA-producing enzyme Gad67, 
and the postsynaptic GABAA 2, in the whole hippocampus and prefrontal cortex of 
SERT-/- rats under basal conditions. We found a significant decrease of Vgat 
expression levels in the hippocampus (-37% vs SERT+/+, p<0.05) (Fig.18A), but not in 
the prefrontal cortex of SERT-/- rats (+16% vs SERT+/+, p>0.05,) (Fig.18F). Gad67 
expression levels were significantly reduced in the hippocampus (-29% vs SERT+/+, 
p<0.01) (Fig.18B) and in the prefrontal cortex (-18% vs SERT+/+, p<0.05) (Fig.18G) of 
SERT-/- rats. To have an indication of inhibitory synapse number in the mutant rat, we 
also investigated the expression of the GABAA 2 receptor subunit. In the 
hippocampus, the receptor expression levels were significantly reduced in SERT-/- rats 
(-38% vs SERT+/+, p<0.05) (Fig.18C). In prefrontal cortex, SERT-/- rats showed a 
reduction of GABAA 2 mRNA levels (-35% vs SERT+/+, p<0.05) (Fig.18H) as well. The 
impairment of the GABAergic system in SERT knockout rats was also associated with 
a dysfunction of two calcium-binding proteins, parvalbumin and calbindin, which 
label subgroups of GABAergic interneurons in the hippocampus and prefrontal cortex 
(Schwaller et al., 2002). Parvalbumin expression was significantly decreased in 
hippocampus (-42% vs SERT+/+, p<0.01) (Fig.18D), and to a less extent in the 
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prefrontal cortex (-25% vs SERT+/+, p<0.05) (Fig.18I) of SERT-/- rats. With respect to 
calbindin, its expression was significantly decreased in the hippocampus (-37% vs 
SERT+/+, p<0.01) (Fig.18E), but not in the prefrontal cortex of SERT-/- rats (-11% vs 
SERT+/+, p>0.05) (Fig.18L).  
 
 
Fig.18 SERT-/- rats show impaired expression of GABAergic markers.  
Vesicular transporter (Vgat; A,F), glutamic acid decarboxylase-67 (Gad67; B,G), GABA A receptor, gamma 2 
(GABAA 2; C,H), Parvalbumin (D,I) and Calbindin (E,L) mRNA levels were measured in the hippocampus (A–E), 
and prefrontal cortex (F–L) of SERT+/+ and SERT-/- rats. The data, expressed as a percentage of +/+ animals (set 
at 100%), are the mean±SEM from 6 to 10 independent determinations.  
*p<0.05, **p<0.01 vs SERT+/+ rats (Student t-test). 
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Given that SERT-/- rats have reduced expression of the neurotrophin Npas4, which has 
been demonstrated to regulate the GABAergic system, we wanted to assess the 
possible correlation between the changes in Npas4 gene expression and the 
alteration in the GABAergic markers in the hippocampus and in the prefrontal cortex. 
The analyses revealed that, Npas4 mRNA levels correlated positively with the 
expression of GABAA 2 mRNA levels in the hippocampus (r = 0.4120, n=24, p<0.05) 
(Fig.19A) as well as in the prefrontal cortex (r = 0.5900, n=24, p<0.01) (Fig.19B), 
suggesting that the lack of the serotonin transporter may be involved in the 
alteration of the GABAergic system and of the factors regulating it. 
 
Fig.19 Npas4 mRNA levels correlated positively with the expression of GABAA 2. 
Correlation analyses between neuronal PAS domain protein 4 (Npas4) and GABAA receptor, gamma 2 (GABAA 
2) in the hippocampus (A) and in the prefrontal cortex (B) of SERT+/+ and SERT-/- rats. Data points in plots 
indicate the amount of Npas4, and GABAA 2 mRNA levels in single rats. Analyses by Pearson’s product–
moment correlation (r). The data, from 24 independent determinations, are expressed as a percentage of 
SERT+ /+/ saline (set at 100%). 
 44 
4.5 Modulation of BDNF expression in SERT mutant rats after exposure to 
maternal deprivation. 
 
Stress represents the major precipitating factor in mood disorders. The effects of 
stress on brain function depend on the timing and duration of the adverse 
experience. In particular the negative influence exerted by early life events on brain 
development can be particularly relevant for later psychopathology since stress will 
impact on structures that are not yet mature (Fumagalli et al., 2008). In order to 
investigate how the interaction between the SERT genotype and the exposure to an 
early life stress (ELS) can affect neuroplasticity, wild type and mutant animals were 
exposed to a maternal deprivation (MD) from PND2 to PND14 (see methods for 
description). 
We performed the analysis of total and long 3’UTR BDNF gene expression in the 
ventromedial and in the dorsomedial prefrontal cortex of SERT+/- and SERT-/-, since 
the two subregions have different anatomical connectivity and functional 
implications (Myers-Schulz and Koenigs, 2012). 
In the ventromedial prefrontal cortex we observed an overall decrease of the two 
BDNF transcripts in both genotypes (Fig.20). As shown in figure 20A, total BDNF 
expression is reduced in heterozygous (-39% vs SERT+/+/no stress, p<0.01) and SERT 
knockout rats (-33% vs SERT+/+/no stress, p<0.05). Following exposure to MD, total 
BDNF mRNA levels are significantly reduced in wild type animals (-46% vs SERT+/+/no 
stress, p<0.001), although the decreased neurotrophin expression in SERT+/- or SERT-/- 
animals was not exacerbated by exposure to ELS. The pool of neurotrophin 
transcripts with long 3’ UTR underwent changes similar to total BDNF. Indeed their 
expression is reduced in SERT-/- animals (-40% vs SERT+/+/no stress, p<0.05), and 
slightly but not significantly decreased in SERT+/- rats (-28% vs SERT+/+/no stress, 
p>0.05). The MD paradigm decreases long 3’UTR BDNF in SERT+/+ rats (-29% vs 
SERT+/+/no stress, p<0.05), but not in mutant animals (Fig.20B).  
 45 
In the dorsomedial prefrontal cortex, the profile of BDNF changes was different. 
Indeed, total mRNA levels (Fig.20C) are not significantly affected in sham SERT+/- or 
SERT-/- rats, whereas they are significantly increased in SERT+/- rats that were exposed 
to MD (+34% vs SERT+/-/no stress, p<0.05). The expression of long 3’ UTR BDNF 
(Fig.20D) is increased in sham SERT+/- animals (+33% vs SERT+/+/no stress, p<0.05) and 
slightly, but not significantly elevated in SERT-/- rats (+24% vs SERT+/+/no stress, 
p>0.05). However the expression of this pool of BDNF transcripts was not significantly 
affected by MD in the three genotypes analysed.  
 
 
Fig.20 Modulation of total BDNF and long 3’UTR BDNF gene expression in SERT+/- and SERT-/- rats after 
exposure to stress.  
Total BDNF (A,C) and long 3’UTR BDNF (B,D) mRNA levels were measured in ventromedial prefrontal cortex 
(A,B) and in the dorsomedial prefrontal cortex (C,D) of SERT+/+, SERT+/- and SERT-/- rats after exposure to 
maternal deprivation stress paradigm. The data, expressed as a percentage of SERT+/+/no stress animals (set at 
100%), are the mean±SEM from 6 to 8 independent determinations.  
*p<0.05, **p<0.01, ***p<0.001 vs SERT+/+/no stress rats; $p<0.05 vs SERT+/-/no stress rats (two-way ANOVA 
with SCPHT). 
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4.6 Modulation of BDNF expression by long-term duloxetine treatment in 
animals with a deletion of the SERT gene. 
 
Since SERT-/- rats show a reduction of total BDNF mRNA levels in the hippocampus 
and in the prefrontal cortex, we decided to investigate the effect of a long-term 
treatment with the antidepressant drug duloxetine (a SNRI, dual blocker of the 
reuptake of the serotonin and norepinephrine) on BDNF expression in SERT-/- rats. 
Indeed there is a general agreement that antidepressant drug treatment can increase 
the expression of BDNF in selected brain regions (Berton and Nestler, 2006; 
Martinowich et al., 2007; Molteni et al., 2010a). In particular we wondered whether 
the antidepressant treatment was able to normalize the alteration of BDNF detected 
in this animal model. To this aim, we measured total BDNF mRNA levels in the whole 
hippocampus and in prefrontal cortex of wild type and SERT-/- rats treated for 21 days 
with duloxetine. 
The mRNA levels of total BDNF are significantly lower in the whole hippocampus of 
vehicle-injected SERT-/- rats (-12% vs SERT+/+/veh, p<0.05). Chronic treatment with 
duloxetine is able to increase total BDNF mRNA levels in wild type (+31% vs 
SERT+/+/veh, p<0.001), as well as in SERT-/- rats (+42% vs SERT-/-/veh, p<0.001) 
(Fig.21A).  
As described above, in the prefrontal cortex we found a significant reduction of total 
BDNF mRNA levels in SERT-/- rats (-34% vs SERT+/+/veh, p<0.001). Long-term 
administration of duloxetine restores the physiological expression of total BDNF in 
mutant rats (+41% vs SERT-/-/veh, p<0.001) and significantly increases the mRNA 
levels of the neurotrophin in SERT+/+ animals (+20% vs SERT+/+/veh, p<0.001) 
(Fig.21B). 
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Fig.21 Long-term duloxetine treatment increases total BDNF mRNA levels in SERT+/+ and SERT-/- rats.  
Total BDNF mRNA levels were measured in hippocampus (A) and prefrontal cortex (B) of SERT+/+ and SERT-/- rats 
treated for 21 days with vehicle (VEH) or duloxetine (DLX) and killed 24 h after the last injection. The data, 
expressed as a percentage of SERT+/+/veh (set at 100%), are the mean±S.E.M. from at least 6 independent 
determinations.  
*p<0.05, ***p<0.001 vs SERT+/+/veh; $$$ p<0.001 vs SERT-/-/veh (two-way ANOVA with SCPHT). 
 
We next decided to investigate the mRNA levels of major BDNF transcripts in the 
whole hippocampus and prefrontal cortex of wild type and mutant rats after long-
term duloxetine treatment.  
Differently from the data of the two distinct hippocampal sub regions, the mRNA 
levels of long 3’UTR BDNF are significantly reduced in the whole hippocampus of 
SERT-/- rats (-13% vs SERT+/+/veh, p<0.05), while BDNF isoform I mRNA levels are not 
decreased (-8% vs SERT+/+/veh, p>0.05). Long-term duloxetine treatment is able to 
increase the expression of the two transcripts in SERT knockout rats (long 3’UTR 
BDNF: +30% vs SERT-/-/veh, p<0.001; exon I: +28% vs SERT-/-/veh, p<0.001) without 
affecting their levels in wild type animals (long 3’UTR BDNF: +8% vs SERT+/+/veh, 
p>0.05; exon I:  +9% vs SERT+/+/veh, p>0.05) (Fig.22A,B). 
On the other hand the mRNA levels of BDNF exon IV and VI in the whole 
hippocampus match the levels found in the two distinct sub regions. In fact the 
expression of the isoforms IV and VI is reduced in the total hippocampus of SERT-/- 
rats (respectively -16% vs SERT+/+/veh, p<0.01; -11% vs SERT+/+/veh, p<0.05). Chronic 
treatment with the antidepressant restores the physiological expression of the two 
transcripts in mutant rats (exon IV: +22% vs SERT-/-/veh, p<0.05; exon VI: +33% vs 
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SERT-/-/veh, p<0.001), but does not affect their modulation in wild type animals (exon 
IV: -10% vs SERT+/+/veh, p>0.05; exon VI: -4% vs SERT+/+/veh, p>0.05) (Fig.22C,D).  
 
 
Fig.22 The modulation of BDNF isoforms after long-term duloxetine treatment is influenced by SERT 
genotype in the  hippocampus. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the hippocampus 
of SERT+/+ and SERT-/- rats treated for 21 days with vehicle (VEH) or duloxetine (DLX) and killed 24 h after the 
last injection. The data, expressed as a percentage of SERT+/+/veh (set at 100%), are the mean±S.E.M. from at 
least 6 independent determinations.  
*p<0.05, **p<0.01 vs SERT+/+/veh; $ p<0.05, $$$ p<0.001 vs SERT-/-/veh (two-way ANOVA with SCPHT). 
 
As described earlier, the expression levels of the four transcripts are reduced in the 
prefrontal cortex of mutant rats (Fig.6A-D). Chronic duloxetine treatment increases 
the mRNA levels of long 3’UTR BDNF and isoforms IV and VI in SERT-/- rats 
(respectively, +25% vs SERT-/-/veh, p<0.05; +51% vs SERT-/-/veh, p<0.001 rats; +73% vs 
SERT-/-/veh, p<0.001) but not in SERT+/+ animals. Conversely the transcriptional 
modulation of isoform I seem to be somewhat different from the other transcripts, 
since duloxetine was able to increase its mRNA levels in wild-type as well as mutant 
rats (+29% vs SERT+/+/veh, p<0.001; +65% vs SERT-/-/veh, p<0.001) (Fig.23A-D). 
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Fig.23 The modulation of BDNF isoforms after long-term duloxetine treatment is influenced by SERT 
genotype in the prefrontal cortex. 
Long 3’UTR BDNF (A), exon I (B), exon IV (C) and exon VI (D) mRNA levels were measured in the prefrontal 
cortex of SERT+/+ and SERT-/- rats treated for 21 days with vehicle (VEH) or duloxetine (DLX) and killed 24 h after 
the last injection. The data, expressed as a percentage of SERT+/+/veh (set at 100%), are the mean±S.E.M. from 
at least 6 independent determinations.  
*p<0.05, **p<0.01, ***p<0.001 vs SERT+/+/veh; $ p<0.05, $$$ p<0.001 vs SERT-/-/veh (two-way ANOVA with 
SCPHT). 
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4.7 Effect of chronic duloxetine treatment on Npas4 and GABAergic markers 
mRNA levels in SERT-/- rats. 
 
We finally tested whether chronic antidepressant treatment might restore the 
physiological expression of Npas4 and GABAergic markers in SERT-/- rats. In 
hippocampus duloxetine normalizes the reduction of Npas4 expression levels in SERT-
/- rats (+98% vs SERT-/-/veh, p<0.01), but did not influence the mRNA levels of the 
transcription factor in wild type animals (+9% vs SERT+/+/veh, p>0.05) (Fig.24A). 
Similarly in the prefrontal cortex the reduced levels of Npas4 are normalized after 
chronic antidepressant treatment in SERT-/- rats (+69% vs SERT-/-/veh, p<0.01), while 
in SERT+/+ animals the antidepressant do not affect Npas4 expression (+17% vs 
SERT+/+/veh, p>0.05) (Fig.24B). 
 
 
 
Fig.24 Chronic duloxetine treatment modulates the levels of Npas4 gene expression in SERT-/- rats.  
Npas4 mRNA levels were measured in the hippocampus (A) and in the prefrontal cortex (B) of SERT+/+ and SERT-
/- rats treated for 21 days with vehicle (VEH) or duloxetine (DLX), and killed 24 h after the last injection. The 
data, expressed as a percentage of SERT+/+/veh (set at 100%), are the mean±SEM from at least five 
independent determinations.  
***p<0.001 vs SERT+/+/veh; $$ p<0.01 vs SERT-/-/veh (two-way ANOVA with SCPHT). 
 
Regarding GABAergic markers we found that long-term duloxetine treatment 
normalizes the reduction of Vgat (+52% vs SERT-/-/veh, p<0.05), Gad67 (+31% vs. 
SERT-/-/veh, p<0.05), and GABAA 2 receptor (+80% vs SERT-/-/veh, p<0.05) in 
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hippocampus of SERT-/- rats, without affecting the mRNA levels of the three 
GABAergic markers in wild type rats (Fig.25A-C). 
In the prefrontal cortex duloxetine increases GABAA 2 expression in wild type (+45% 
vs SERT+/+/veh, p<0.05) as well as in mutant rats (+91% vs SERT-/-/veh, p<0.001) 
(Fig.25H). However, differently from the hippocampus, the antidepressant treatment 
was not able to modulate Gad67 (-4%, vs SERT-/-/veh, p>0.05) and Vgat (-7% vs SERT-/-
, p>0.05) mRNA levels in SERT-/- animals (Fig.25F,G). 
Duloxetine treatment is also able to modulate parvalbumin and calbindin in the 
hippocampus and in the prefrontal cortex. Specifically, chronic antidepressant 
treatment restored parvalbumin (+52% vs SERT-/-/veh, p<0.05) and calbindin (+79% vs 
SERT-/-/veh, p<0.01) physiological levels in the hippocampus of SERT-/- rats (Fig.23D,E). 
Conversely in the prefrontal cortex nor parvalbumin (+19% vs SERT-/-/veh, p>0.05), 
neither calbindin (+8% vs SERT-/-/veh, p>0.05) are affected by long-term duloxetine 
administration (Fig.25I,L). 
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Fig.25 SERT-/- rats show impaired expression of GABAergic markers: modulation by chronic duloxetine 
treatment.  
Vesicular transporter (Vgat; A,F), glutamic acid decarboxylase-67 (Gad67; B,G), GABA A receptor, gamma 2 
(GABAA 2; C,H), Parvalbumin (D,I) and Calbindin (E,L) mRNA levels were measured in the hippocampus (A–E), 
and prefrontal cortex (F–L) of SERT+/+ and SERT-/- rats treated for 21 days with vehicle (VEH) or duloxetine (DLX), 
and killed 24 h after the last injection. The data, expressed as a percentage of +/+ animals (set at 100%), are the 
mean±SEM from 6 to 10 independent determinations.  
*p<0.05, **p<0.01 vs SERT+/+/veh rats: $ p<0.05, $$ p<0.001, $$$ p<0.001 vs SERT-/-/veh rats (two-way ANOVA 
with SCPHT) 
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5. DISCUSSION 
 
Animals with a target deletion of the serotonin transporter represent a model of 
anxiety and depressive behavior (Olivier et al., 2008) and can be used to investigate 
the mechanisms that may underlie such phenotype. In line with the concept that 
several psychiatric conditions, such as mood disorders, are associated with deficits or 
impairment of neuronal plasticity (McClung and Nestler, 2008; Pittenger and Duman, 
2008, Calabrese et al., 2011), we demonstrate that, under basal condition, adult SERT-
/- rats have decreased expression of the neurotrophin BDNF, a major player in 
neuronal plasticity. We found that SERT-/- rats have reduced BDNF expression in the 
ventral hippocampus, that specifically modulates emotional and affective processes, 
and in the prefrontal cortex, but not in the dorsal hippocampus involved in spatial 
learning and memory function. Interestingly, within the prefrontal cortex a partial 
deletion of the SERT gene, as occurring in SERT+/− rats, is sufficient to determine a 
significant reduction of BDNF expression. 
The analysis of BDNF different transcripts suggests that the effects observed in the 
ventral hippocampus of mutant rats are primarily due to a reduction of isoform I and 
IV, whereas a more generalized decrease was found in the prefrontal cortex of SERT-/- 
rats. Furthermore in heterozygous rats we found a reduction of exon I in the ventral 
hippocampus, and of exon I and IV in prefrontal cortex. 
Changes in the neurotrophin expression observed in prefrontal cortex and 
hippocampus of rats with partial deletion of SERT may hold translational implications, 
since heterozygous SERT rats mimic more closely the human condition of reduced 
expression of the serotonin transporter in individuals carrying the S allele gene. In 
line with this possibility, our laboratory has previously demonstrated that BDNF 
expression is significantly reduced in peripheral cells of control individuals carrying 
the S allele for the 5-HTTLPR (Molteni et al., 2010a).  
The more generalized effect of SERT deletion within the prefrontal cortex may be 
related to structural alterations in this brain region. Neuroimaging studies have 
indeed demonstrated that short allele carriers, who have lower SERT expression, 
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showed reduced gray matter volume in limbic regions (Pezawas et al., 2008). 
Moreover, changes in the expression of selected BDNF transcripts, as occurring in 
SERT mutant rats, may reflect altered function of neurotransmitter systems or circuits 
involved in the control of BDNF production. 
The down-regulation of total BDNF mRNA levels is paralleled by a similar reduction of 
mature BDNF protein levels in the crude synaptosomal fraction of ventral 
hippocampus, whereas in the dorsal hippocampus and in the prefrontal cortex only 
the levels of proBDNF are reduced. These data suggest that despite similar changes at 
mRNA levels, the regulation of BDNF protein in the ventral hippocampus and the 
prefrontal cortex can be different. 
Deletion of SERT gene in mice (Holmes et al., 2003; Lira et al., 2003) and rats (Olivier 
et al., 2008) produces anxiety- and depression-related behaviors, an effect that may 
appear paradoxical given that chronic administration of SSRI antidepressant, which 
blocks SERT function, results in antidepressant effects. Indeed the anxious and 
depressed phenotype of SERT-/- mice may represent the long-lasting consequence of 
impaired SERT function during early development (Ansorge et al., 2008; Ansorge et 
al., 2004). 
As expected, we show that reduced expression of BDNF in SERT-/- rats is not due to 
adult impairment of the transporter. In fact chronic treatment of adult wild-type rats 
with the SSRI fluoxetine increased BDNF gene expression rather than reduced it. 
These findings are in line with data from several laboratories that during the last 10-
15 years have clearly shown that repeated treatment with antidepressant drugs up-
regulates BDNF expression in different brain structures, an effect that may normalize 
defective neuronal plasticity in depressed subjects (Calabrese et al., 2007; Duman 
and Monteggia, 2006; Molteni et al., 2010a).  
Moreover SERT blockade from postnatal days 4 to 21 (as produced by fluoxetine 
treatment) may not be sufficient to determine a long-lasting reduction of BDNF 
expression, although a transient decrease of the neurotrophin can be observed 
during the second week of postnatal life (Karpova et al., 2009).  
Hence, the reduction of BDNF levels in SERT-/- rats may not be due to early postnatal 
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impairment of the transporter but may encompass altered SERT function in utero as 
well as during adolescence. 
In order to understand the developmental profile of the neuroplastic alteration in 
mutant rats, we therefore investigated BDNF expression from birth to post natal day 
(PND) 28. The present data demonstrate that alterations of BDNF expression 
following genetic inactivation of SERT originates early in development and worsens 
during the first 2-3 weeks of postnatal life, suggesting that the maturational profile of 
the serotonergic system (Daws and Gould, 2011) may interfere with the 
developmental maturation of the neurotrophin in key brain regions. This may shape 
the path towards permanent alterations of neuroplasticity in selected brain regions 
including the hippocampus and the prefrontal cortex. 
In particular, the analysis of the developmental profile of the neurotrophin in the 
ventral hippocampus suggests that, while BDNF mRNA levels increase physiologically 
between PND0 and PND28 in wild-type animals, its expression reaches a plateau 
around the end of the second week of life in SERT-/- rats. On the other hand in the 
dorsal hippocampus BDNF is decreased in SERT-/- rats during the first four weeks. 
However, the reduction of the neurotrophin seems to have a limited duration, since it 
normalizes at adulthood. At cortical level, the lack of SERT significantly and markedly 
affected BDNF expression after the first week of life, a week earlier than in the 
ventral hippocampus.  
In accordance with transcriptional changes, we demonstrated that the protein levels 
of mature BDNF were decreased in the crude synaptosomal fraction at PND21 
whereas limited changes were present at PND7, both in the ventral hippocampus as 
well as in the prefrontal cortex. Considering the complex BDNF regulation, the 
reduction of its protein levels in the crude synaptosomal fraction is indicative of 
deficit in the pool of neurotrophin ready available for release, which is important for 
synaptic mechanisms and cell-cell communication (Poo, 2001; Calabrese et al., 2007; 
Molteni et al., 2010a; Lau et al., 2010). 
The different modulation of BDNF mRNA levels at adulthood could be the 
consequences of abnormalities in transcription factors regulating its expression. In 
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line with this possibility, we demonstrated that total deletion of SERT affect the 
expression of the transcription factors Npas4, CREB and CaRF, which play a primary 
role in the transcription of BDNF exon IV, the most abundant BDNF transcript. In 
agreement with the expression levels of exon IV, we demonstrated that the mRNA 
levels for all these transcription factors are significantly reduced in the ventral 
hippocampus. In the dorsal hippocampus we found only the reduction of Npas4, 
which seems not enough to induce a decrease of transcript IV expression. Conversely, 
in the prefrontal cortex Npas4 and CaRF are reduced, while CREB levels are 
unchanged, supporting the hypothesis that CREB may be more involved in the 
activity-regulated expression of BDNF exon IV, rather than controlling its levels under 
resting conditions (Hong et al., 2008).  
The different profile of BDNF expression in SERT-/- rats may also be the consequence 
of other systems controlling the regulation of the neurotrophin such as epigenetic 
mechanisms. In particular, it has been our laboratory that has previously 
demonstrated an increased DNA methylation in the promoter region of exon VI, 
which can correlate with the repression of its transcription in the hippocampus of 
SERT-/- rats. Conversely, the downregulation of BDNF exon IV mRNA levels is 
associated with reduced acetylation of histone H3, a mechanism driving transcription 
activation (Molteni et al., 2010a).  
One system lying downstream from Npas4 and BDNF that may be relevant for the 
phenotype of SERT mutants is GABA. Indeed, Npas4 regulates the development of 
GABAergic synapses, since Npas4 gene silencing leads to reduced expression of 
GABAergic markers, including the presynaptic GABA-producing enzymes Gad65, 
Gad67, and the GABAA 2 receptor subunit (Lin et al., 2008). We demonstrate that 
SERT-/- rats show a strong impairment of the GABAergic system in the whole 
hippocampus as well as in prefrontal cortex, although some differences exist 
between these two structures. In fact, the expression of Vgat, is significantly reduced 
only in the hippocampus of SERT-/- rats, suggesting that these animals may display a 
reduced number of GABAergic terminals, whereas the expression of the GABA 
synthesizing enzyme Gad67 or the postsynaptic GABAA-2 was similarly reduced in 
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the hippocampus and prefrontal cortex of mutant rats. Moreover, genetic deletion of 
SERT may influence the sub-population of GABAergic neurons, as the expression of 
parvalbumin was decreased in both structures, whereas calbindin, which labels a 
small sub-group of interneurons, was reduced only in the hippocampus. Disturbances 
in the anatomy and function of the GABAergic system have been postulated in animal 
models of depression and in different stress-related psychiatric disorders (Sanacora 
et al., 1999; Benes and Berretta, 2001; Krystal et al., 2002; Brambilla et al., 2003; 
Luscher et al., 2011). In fact, GABAA receptors can be downregulated in different 
brain regions of rats exposed to the learned helplessness paradigm (Drugan et al., 
1992), whereas lower CSF and plasma GABA levels have been found in depressed 
patients, as compared with control subjects (Kasa et al., 1982; Gerner et al., 1984; 
Petty et al., 1992). On these bases, the defects of hippocampal GABAergic markers in 
SERT-/- animals may contribute to the anxious/depressive phenotype observed in 
these animals (Olivier et al., 2008). 
In addition to the genetic component, stressful experiences can exacerbate or 
precipitate depressive disorder. Adverse events early in life can be particularly 
relevant for later psychopathology since they will impact on structures that are not 
fully mature. We demonstrated that exposure to the maternal deprivation paradigm 
reduce the expression of both total and long 3’UTR BDNF transcripts in the 
ventromedial prefrontal cortex of wild type animals, without exacerbating the 
already reduced mRNA levels of the neurotrophin in SERT+/- and SERT-/- rats. The 
present results suggest that within the ventromedial prefrontal cortex BDNF 
expression is similarly reduced by SERT deletion or exposure to ELS, which can 
independently produce long-lasting depressive-like behaviour (Holmes et al., 2003; 
Fumagalli et al., 2007; Olivier et al., 2008). However the combination of MD with the 
susceptible genotype does not lead to a worsening of the neuroplastic phenotype 
(BDNF expression). This may suggest that there is a floor effect in the regulation of 
BDNF expression, which will render difficult the identification for the gene * 
environment interaction. Future studies will try to establish if milder or shorter stress 
paradigms could be employed in order to address this important issue, which holds 
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high translational relevance. 
In the dorsomedial prefrontal cortex, involved in cognition and memory function 
(Dalley et al., 2004) we found a complete different modulation of the neurotrophin. 
BDNF mRNA levels are not modulated by stress in wild type or knockout rats. 
Heterozygous animals, on the other hand, show increased expression of long 3’UTR 
transcripts, while MD can increase total BDNF expression only in SERT+/- rats. This 
suggests that there are anatomically-specific changes of BDNF expression, which may 
subserve different functions. For example, recent findings demonstrated that humans 
and nonhuman primates carrying the S variant of the serotonin transporter 
outperform subjects carrying the long allele in a wide array of cognitive tasks and 
show increased social conformity (Homberg and Lesch, 2011).  
Finally, we show that chronic treatment with the antidepressant duloxetine is able to 
normalize BDNF mRNA levels, which are reduced in the whole hippocampus and 
prefrontal cortex of SERT-/- rats. As demonstrated previously (Calabrese et al., 2007; 
Molteni et al., 2010a), long-term duloxetine treatment increases total BDNF mRNA 
levels in the hippocampus and in the prefrontal cortex of wild-type animals.  
Moreover, we demonstrate that the mRNA levels of the long 3’ UTR BDNF and of 
transcripts I, IV and VI are normalized after duloxetine treatment in SERT knockout 
rats. This modulation suggest, that higher levels of long 3’ UTR BDNF mRNA may 
enhance the synaptic pool of BDNF transcripts that, upon stimuli, may undergo local 
translation (An et al., 2008). Moreover the modulation of isoforms I, IV and VI might 
represent a specific mechanism through which antidepressant drugs, such as 
duloxetine, can restore defective plasticity in a vulnerable genotype. 
Chronic duloxetine treatment is also able to normalize the reduced expression of 
Npas4 in the hippocampus and prefrontal cortex of SERT-/- rats, without altering 
transcription factor levels in wild-type animals, suggesting that the effect of the 
antidepressant may be considered a restorative mechanism rather than a general 
potentiation of Npas4-dependent transcription. As a consequence of BDNF and 
Npas4 modulation following duloxetine treatment in SERT-/- rats, we also show that 
the impairment of the GABAergic system in the hippocampus and in the prefrontal 
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cortex of SERT-/- rats can be normalized by long-term treatment with the SNRI 
antidepressant. Duloxetine appears to be highly effective on hippocampal alterations, 
where all GABAergic abnormalities in SERT-/- rats (Vgat, Gad67, GABAA 2, 
parvalbumin, and calbindin) are normalized by antidepressant treatment, whereas 
within the prefrontal cortex, duloxetine appears to restore only the expression of 
GABAA 2. 
In summary, since depression vulnerability can be associated with impaired neuronal 
plasticity (McClung and Nestler, 2008), we suggest that the reduced expression of 
BDNF in animals carrying a deletion of the SERT gene may contribute to their 
pathologic phenotype. This impairment originates early in development and is 
associated with reduction of transcription factors and GABAergic markers, suggesting 
that these defects may contribute to behavioral phenotype associated with SERT-/-, 
and in particular those that are relevant for anxiety and depression. Moreover these 
animals maintain the ability to show neuroplastic changes in response to 
antidepressant drugs, possibly via the blockade of the noradrenaline transporter. The 
molecular characterization of the SERT mutant rat may prove useful to elucidate the 
pathophysiology of the depressive disorder and may eventually lead to the 
development of new effective treatments. 
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